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See Article, pages 995–1003During the past decades, hepatocellular carcinoma (HCC) became
a major health burden and currently represents the third leading
cause of cancer-related mortality worldwide [1]. While a contin-
uous decline in cirrhosis-related mortality was observed over the
past decades, mortality rates for HCC increased until the end of
the last millennium. In fact, the incidence of HCC still nearly
equals its mortality rate [2]. The introduction of the multi tyro-
sine kinase inhibitor sorafenib represented a major breakthrough
for the therapy of HCC [3]. However, despite extensive efforts,
other chemotherapeutic agents and also alternative tyrosine
kinase inhibitors did not show a signiﬁcant beneﬁt for HCC
patients and it is currently unclear which therapeutic strategies
beyond sorafenib will be available in the future [4]. It is well
established that in most instances HCC arises in a setting of
chronic hepatic inﬂammation, but the knowledge on this unique
association between inﬂammation and cancer has not yet trans-
lated into preventive or therapeutic concepts against HCC in
patients with chronic liver disease [5], highlighting the need for
a better understanding of the function of inﬂammatory signaling
pathways in hepatocarcinogenesis.
Among the cytokines that can induce inﬂammation, tumour
necrosis factor (TNF) withholds a privileged role in the chroni-
cally inﬂamed liver [6]. After its binding to TNF receptors 1
(TNFR1) or 2 (TNFR2), several distinct protein complexes can be
assembled, leading to the activation of different signaling path-
ways, such as the pro -survival and -inﬂammatory NF-jB path-
way, the stress-related Jun-(N)-terminal kinase (JNK) and
p38MAPK pathways or the pro-apoptotic caspase cascade [7]. In
addition to phosphorylation events, the activation status of these
respective signaling pathways is tightly controlled by ubiquitina-
tion, which involves the attachment of one or several ubiquitin
molecules to a substrate [8]. Until recently, ubiquitination was
mainly considered to play a role in controlling the half-life of pro-
teins, but it soon became apparent that ubiquitination also regu-
lates signaling events by acting as modulator of the enzymatic
activity or docking of regulatory molecules [8]. To add anJournal of Hepatology 20
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cess that can be counterbalanced by deubiquitinase enzymes,
including the molecule CYLD. CYLD was initially discovered in
patients with familial cylindromatosis, a rare inherited cancer,
characterized by the formation of benign tumours in hairy parts
of the body [9]. Later, the group of Gilles Courtois could show that
CYLD is an essential modiﬁer of NF-jB and the ubiquitination
state of the NF-jB-activating molecule NEMO [10]. In addition
to NF-jB, various studies performed mainly in cell culture
revealed that CYLD deubiquitinates multiple other members of
the TNF-signaling cascade, including TGF-b-activated kinase-1
(TAK1) and the TRAF family of ligases [11] (Fig. 1). Interestingly,
expression of CYLD was shown to be dysregulated in several
human cancers, including lung and colon cancer and multiple
myeloma [12].
In the paper from the group of Henning Schulze-Bergkamen
published in the present issue of the Journal of Hepatology [13],
the authors examined the role of CYLD in liver homeostasis and
the development of HCC by applying a conditional, cre/loxP-
based knockout approach of CYLD in parenchymal liver cells. Spe-
ciﬁcally, they did not ablate the whole CYLD protein but only
exons 7/8, resulting in overexpression of a naturally occurring,
shorter splicing version of CYLD (s-CYLD) that preserves its cata-
lytic activity but lacks the 3rd CAP domain of the protein respon-
sible for binding of e.g., NEMO and TRAF2 [10,14] (CYLDxAlbCre).
Expression of this mutant form in CYLDxAlbCre animals resulted
in a spontaneous phenotype characterized by prominent biliary
ﬁbrosis and ductular reaction, reﬂecting a chronic inﬂammatory
response with immune cell inﬁltration and overexpression of
inﬂammatory cytokines and chemokines such as TNF, IL-6, and
MCP-1. However, in contrast to other genetic models of chronic
hepatic inﬂammation [15,16], CYLDxAlbCre mice did not develop
spontaneous HCCs, but were more susceptible to liver tumours
induced by the chemical carcinogen diethylnitrosamine (DEN).
Interestingly, some liver tumours in CYLDxAlbCre mice showed
histological characteristics of cholangiocellular carcinomas
(CCC). On the one hand, this might be explained by the fact that
the albumin-Cre line used in this paper is not speciﬁc for hepato-
cytes but mediates deletion in a parenchymal hepatic precursor
cell compartment [17]. On the other hand, the detection of CCCs
in CYLDxAlbCre mice might support recently published ﬁndings
by the group of Holger Willenbring showing that CCC can directly12 vol. 57 j 937–939
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Fig. 1. After binding to its receptor (TNFR1), TNF induces trimerization of the
receptor and recruitment of the protein complex I, among others including
the adapter protein TRADD, the ubiquitin ligases TRAF2/TRAF5 and the
protein kinase RIP1. This complex promotes NF-jB activation through ubiqui-
tination and subsequent recruitment of TAK and the IKK complex. The kinase
TAK1 is responsible for the activation of JNK and p38MAPK. CYLD deubiquitinates
several molecules of complex I including TRAF2, TAK1 and NEMO, thereby
facilitating the formation of complex II, consisting of RIP1, FADD, and procaspase
8, which then initiates apoptosis. Nevertheless, this apoptotic pathway can be
inhibited by a sufﬁcient NF-jB stimulation inducing transcription of caspase
inhibitors like cFLIP. TNF, tumour necrosis factor; TRADD, tumor necrosis factor
receptor type 1-associated death domain; RIP1, receptor-interacting protein 1;
TRAF2/5, TNF receptor-associated factor 2/5; FADD, Fas-associated protein with
death domain; JNK, Jun-(N)-terminal-kinase; NEMO, NF-jB essential modulator,
TAK1, TGF-b-activated kinase-1; p38MAPK, p38 MAP kinase.
Editorial
938 Journal of Hepatology 201evolve from hepatocytes by a pathway involving NOTCH and AKT
signalling [18]. Finally, the authors demonstrated that their spon-
taneous phenotype was associated with a subtle increase in NF-
jB signaling reﬂected by upregulation of NF-jB target genes like
survivin and GADD45b.
The study makes an important contribution to the ﬁeld of
inﬂammation and hepatocarcinogenesis, since it clearly demon-
strates a novel, interesting function of CYLD in HCC development.
However, like every good study, it leaves unanswered questions
on top of the novel ﬁndings presented. While the authors demon-
strated increased NF-jB activity in CYLDxAlbCre animals, it is
presently not clear if NF-jB is really the main downstream target
of CYLDmediating its anti-carcinogenic function, given the multi-
ple other interaction partners of CYLD within the TNF pathway.
Of note, it was previously demonstrated that blockage of NF-jB
results in increased hepatic tumourigenesis in the DEN-HCC-
model [19]. Therefore, it is unclear if the opposite situation in
CYLDxAlbCre mice – overactivation of NF-jB – really functionally
explains increased tumourigenesis in these animals. In contrast,
the phenotype in CYLDxAlbCre animals might be a consequence
not of the absence of full-length-CYLD, but of the increased intra-
cellular amount of the short-CYLD-version, putatively lacking
binding sites to certain factors like NEMO and TRAF2 in exons
7/8, but still retaining the deubiquitinase-activity encoded from
exon 9 on.
Important complementary information to the present study
might come from a recent paper published in the journal Cancer
Cell by the group of Iannis Talianidis [20]. In contrast to the pres-
ent approach, this group performed a conditional knockout of
exon 9 of CYLD, resulting in expression of a deubiquitinase-
deﬁcient form of CYLD similar to oncogenic mutations described
in humans [21]. Interestingly, expression of this mutant in liver
cells resulted in spontaneous development of hepatic ﬁbrosis
and liver tumours. On a functional level, certain features of the
phenotype seen in that CYLD mutant mouse were mediated
through the kinase TAK1, since combined deletions of TAK1 and
CYLD led to less ﬁbrosis and periportal cell death than those
observed in CYLD single mutants. However, TAK1/CYLD com-
bined mutant animals still showed cancer development and other
features of TAK1 single mutant animals [15], demonstrating that
neither the absence nor the over-activation of TAK1 is beneﬁcial
for liver cells. Nevertheless, given that absence of the deubiqu-
itinase-activity of CYLD results in a much more dramatic pheno-
type than the exon 7/8 deletion presented in the current paper, it
would be of high interest to identify the interaction partners of
CYLD that still bind to the short form (s-CYLD) and prevent cell
death and spontaneous cancer in CYLDxAlbCre animals. In the
light of these two interesting studies and the elegant approach
of partial deletion of certain exons in the Cyld gene, it is possible
that future studies taking similar approaches rather than a com-
plete genetic knockout might lead to novel important functional
knowledge of key players in inﬂammation and cancer, since they
are probably closer to mutations observed in human cancer and
also more relevant to pharmacological applications.Conﬂict of interest
The authors declared that they do not have anything to disclose
regarding funding or conﬂict of interest with respect to this
manuscript.2 vol. 57 j 937–939
JOURNAL OF HEPATOLOGY
References
[1] Sherman M. Hepatocellular carcinoma: epidemiology, surveillance, and
diagnosis. Semin Liver Dis 2010;30:3–16.
[2] Cabibbo G, Craxi A. Epidemiology, risk factors and surveillance of hepato-
cellular carcinoma. Eur Rev Med Pharmacol Sci 2010;14:352–355.
[3] de Lope CR, Tremosini S, Forner A, Reig M, Bruix J. Management of HCC. J
Hepatol 2012;56:S75–S87.
[4] Villanueva A, Llovet JM. Targeted therapies for hepatocellular carcinoma.
Gastroenterology 2011;140:1410–1426.
[5] Vucur M, Roderburg C, Bettermann K, Tacke F, Heikenwalder M, Trautwein C,
et al. Mouse models of hepatocarcinogenesis: what can we learn for the
prevention of human hepatocellular carcinoma? Oncotarget
2010;1:373–378.
[6] Tacke F, Luedde T, Trautwein C. Inﬂammatory pathways in liver homeostasis
and liver injury. Clin Rev Allergy Immunol 2009;36:4–12.
[7] Luedde T, Schwabe RF. NF-kappaB in the liver-linking injury, ﬁbrosis and
hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol 2011;8:108–118.
[8] Karin M, Gallagher E. TNFR signaling: ubiquitin-conjugated TRAFﬁc signals
control stop-and-go for MAPK signaling complexes. Immunol Rev
2009;228:225–240.
[9] Bignell GR, Warren W, Seal S, Takahashi M, Rapley E, Barfoot R, et al.
Identiﬁcation of the familial cylindromatosis tumour-suppressor gene. Nat
Genet 2000;25:160–165.
[10] Kovalenko A, Chable-Bessia C, Cantarella G, Israel A, Wallach D, Courtois G.
The tumour suppressor CYLD negatively regulates NF-kappaB signalling by
deubiquitination. Nature 2003;424:801–805.
[11] Courtois G. Tumor suppressor CYLD: negative regulation of NF-kappaB
signaling and more. Cell Mol Life Sci 2008;65:1123–1132.Journal of Hepatology 201[12] Massoumi R. CYLD: a deubiquitination enzyme with multiple roles in cancer.
Future Oncol 2011;7:285–297.
[13] Urbanik T, Boger RJ, Longerich T, Becker K, Ehrenberg KR, Hovelmeyer N,
et al. Liver speciﬁc deletion of CYLDexon7/8 induces severe biliary damage,
ﬁbrosis and increases hepatocarcinogenesis in mice. J Hepatol
2012;57:995–1003.
[14] Trompouki E, Hatzivassiliou E, Tsichritzis T, Farmer H, Ashworth A, Mosialos
G. CYLD is a deubiquitinating enzyme that negatively regulates NF-kappaB
activation by TNFR family members. Nature 2003;424:793–796.
[15] Bettermann K, Vucur M, Haybaeck J, Koppe C, Janssen J, Heymann F, et al.
TAK1 suppresses a NEMO-dependent but NF-kappaB-independent pathway
to liver cancer. Cancer Cell 2010;17:481–496.
[16] Luedde T, Beraza N, Kotsikoris V, van Loo G, Nenci A, De Vos R, et al. Deletion
of NEMO/IKKgamma in liver parenchymal cells causes steatohepatitis and
hepatocellular carcinoma. Cancer Cell 2007;11:119–132.
[17] Xu X, Kobayashi S, Qiao W, Li C, Xiao C, Radaeva S, et al. Induction of
intrahepatic cholangiocellular carcinoma by liver-speciﬁc disruption of
Smad4 and Pten in mice. J Clin Invest 2006;116:1843–1852.
[18] Fan B, Malato Y, Calvisi DF, Naqvi S, Razumilava N, Ribback S, et al. Cholangio-
carcinomas can originate from hepatocytes in mice. J Clin Invest 2012.
[19] Maeda S, Kamata H, Luo JL, Leffert H, Karin M. IKKbeta couples hepatocyte
death to cytokine-driven compensatory proliferation that promotes chem-
ical hepatocarcinogenesis. Cell 2005;121:977–990.
[20] Nikolaou K, Tsagaratou A, Eftychi C, Kollias G, Mosialos G, Talianidis I.
Inactivation of the deubiquitinase CYLD in hepatocytes causes apoptosis,
inﬂammation, ﬁbrosis, and cancer. Cancer Cell 2012;21:738–750.
[21] Trompouki E, Tsagaratou A, Kosmidis SK, Dolle P, Qian J, Kontoyiannis DL,
et al. Truncation of the catalytic domain of the cylindromatosis tumor
suppressor impairs lung maturation. Neoplasia 2009;11:469–476.2 vol. 57 j 937–939 939
